Paper. Feifel D, Seynaeve M, Cubala WJ et al.. JAMA, 26 Oct 2026.
Tags: Human, RCT, Psilocybin, LSD, Ketamine, 5-MeO-DMT, Depression.
Intranasal mebufotenin for treatment-resistant depression reported in JAMA, with discharge time as a co-headline.
Adults with depression nonresponsive to 2-5 antidepressant trials were randomised at 38 sites to a single intranasal dose of 8 mg (n=46), 12 mg (n=73), or 0.3 mg, with 8 weeks of blinded follow-up. The logistical claim is the point: 5-MeO-DMT's experience is brief, so in-clinic monitoring is short.
How much weight it carries: Phase 2b, 38 sites, double-blind with 8-week follow-up; the control was a 0.3 mg active dose rather than inert placebo, so effects are dose contrasts. (Humans, RCT, Double-blind, Controlled, n = 119)
